"Type 2 diabetes has a new treatment option available--the FDA has approved a new once-daily tablet, Tradjenta, to help people with the disease control their blood sugar.
WebMD reports that Tradjenta (linagliptin) is a DPP-4 inhibitor, placing it in the same class as Januvia and Onglyza. Like other DPP-4 inhibitors, Tradjenta can be taken with other diabetes treatment options, like metformin.
'This approval provides another treatment option for the millions of Americans with type 2 diabetes,' Mary Parks, MD, director of the FDA's division of metabolism and endocrinology products, says in a news release. 'It is effective when used alone or when added to existing treatment regimens.'"
WebMD reports that Tradjenta (linagliptin) is a DPP-4 inhibitor, placing it in the same class as Januvia and Onglyza. Like other DPP-4 inhibitors, Tradjenta can be taken with other diabetes treatment options, like metformin.
'This approval provides another treatment option for the millions of Americans with type 2 diabetes,' Mary Parks, MD, director of the FDA's division of metabolism and endocrinology products, says in a news release. 'It is effective when used alone or when added to existing treatment regimens.'"
No hay comentarios:
Publicar un comentario
Nota: solo los miembros de este blog pueden publicar comentarios.